Published in Brain Sci on September 20, 2012
Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA (2000) 14.17
The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) (2002) 9.90
Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology (2001) 9.25
Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. Nature (2001) 5.65
Evidence for addiction-like behavior in the rat. Science (2004) 5.19
Neuroadaptation. Incubation of cocaine craving after withdrawal. Nature (2001) 5.14
Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry (2005) 4.80
An opponent-process theory of motivation. I. Temporal dynamics of affect. Psychol Rev (1974) 4.65
Drug seeking becomes compulsive after prolonged cocaine self-administration. Science (2004) 4.20
Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. Arch Gen Psychiatry (1986) 3.74
Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J Neurosci (2006) 2.74
Drug addiction and the memory systems of the brain. Ann N Y Acad Sci (2008) 2.36
Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study. Br J Psychiatry (1989) 1.98
Time-dependent changes in extinction behavior and stress-induced reinstatement of drug seeking following withdrawal from heroin in rats. Psychopharmacology (Berl) (2001) 1.87
Brain substrates for increased drug seeking during protracted withdrawal. Neuropharmacology (2004) 1.50
Relapse to heroin-seeking in rats under opioid maintenance: the effects of stress, heroin priming, and withdrawal. J Neurosci (1996) 1.38
Opponent process theory of motivation: neurobiological evidence from studies of opiate dependence. Neurosci Biobehav Rev (1989) 1.33
Unlimited access to heroin self-administration: independent motivational markers of opiate dependence. Neuropsychopharmacology (2006) 1.29
Multiple roles for orexin/hypocretin in addiction. Prog Brain Res (2012) 1.26
Prolonged tolerance, dependence and abstinence following subcutaneous morphine pellet implantation in the rat. Eur J Pharmacol (1994) 1.26
The role of hypocretin in driving arousal and goal-oriented behaviors. Brain Res (2009) 1.25
Enhanced morphine preference following prolonged abstinence: association with increased Fos expression in the extended amygdala. Neuropsychopharmacology (2003) 1.19
Stimuli associated with a single cocaine experience elicit long-lasting cocaine-seeking. Nat Neurosci (2004) 1.15
Changes in catecholaminergic pathways innervating paraventricular nucleus and pituitary-adrenal axis response during morphine dependence: implication of alpha(1)- and alpha(2)-adrenoceptors. J Pharmacol Exp Ther (2000) 1.08
Classical conditioning of a morphine abstinence phenomenon, reinforcement of opioid-drinking behavior and "relapse" in morphine-addicted rats. Psychopharmacologia (1967) 1.06
Morphine-induced long-term sensitization to the locomotor effects of morphine and amphetamine depends on the temporal pattern of the pretreatment regimen. Psychopharmacology (Berl) (1997) 1.06
Opiate withdrawal-induced place aversion lasts for up to 16 weeks. Psychopharmacology (Berl) (2000) 1.01
Intermittent morphine administration induces dependence and is a chronic stressor in rats. Neuropsychopharmacology (2003) 1.01
Robust escalation of nicotine intake with extended access to nicotine self-administration and intermittent periods of abstinence. Neuropsychopharmacology (2012) 0.95
Physiological parameters of morphine dependence in man--tolerance, early abstinence, protracted abstinence. J Psychiatr Res (1969) 0.93
Total neurochemical lesion of noradrenergic neurons of the locus ceruleus does not alter either naloxone-precipitated or spontaneous opiate withdrawal nor does it influence ability of clonidine to reverse opiate withdrawal. J Pharmacol Exp Ther (1999) 0.93
Opiate withdrawal signs precipitated by naloxone following a single exposure to morphine: potentiation with a second morphine exposure. Psychopharmacology (Berl) (1997) 0.92
Intravenous self-administration of drugs in rats. J Pharmacol Exp Ther (1978) 0.92
Motivational control of heroin seeking by conditioned stimuli associated with withdrawal and heroin taking by rats. Behav Neurosci (2006) 0.91
Differential responsivity of the hypothalamic-pituitary-adrenal axis to glucocorticoid negative-feedback and corticotropin releasing hormone in rats undergoing morphine withdrawal: possible mechanisms involved in facilitated and attenuated stress responses. J Neuroendocrinol (2001) 0.89
Opioid physical dependence development: effects of single versus repeated morphine pretreatments and of subjects' opioid exposure history. Psychopharmacology (Berl) (1994) 0.89
Role of withdrawal in reinstatement of morphine-conditioned place preference. Psychopharmacology (Berl) (2005) 0.88
Alterations in corticotropin-releasing factor and vasopressin content in rat brain during morphine withdrawal: correlation with hypothalamic noradrenergic activity and pituitary-adrenal response. J Pharmacol Exp Ther (1998) 0.88
Heroin, 6-acetylmorphine and morphine effects on threshold for rewarding and aversive brain stimulation. J Pharmacol Exp Ther (1992) 0.85
Circadian alteration in neurobiology during 30 days of abstinence in heroin users. Biol Psychiatry (2009) 0.84
Self-administration of heroin, acetylmethadol, morphine, and methadone in rhesus monkeys. Life Sci (1978) 0.83
Diurnal variation in cue-induced responses among protracted abstinent heroin users. Pharmacol Biochem Behav (2008) 0.82
Dorsal and median raphe serotonergic system lesion does not alter the opiate withdrawal syndrome. Pharmacol Biochem Behav (2002) 0.80
Sleep impairments in rats implanted with morphine pellets. Neuropsychobiology (1999) 0.76
Decline in the mean integrated electroencephalogram voltage during morphine abstinence in the rat. J Pharmacol Exp Ther (1971) 0.76